SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program [Yahoo! Finance]
Thermo Fisher Scientific Inc (TMO)
Last thermo fisher scientific inc earnings: 4/22 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
ir.thermofisher.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
Earnings rose 99% year over year, driven by encouraging product sales during the quarter. The adjusted earnings did not include depreciation and amortization expenses and stock-based compensation costs. Including these items, EPS was 34 cents against the year-ago period's reported loss of 46 cents. Sarepta recorded total revenues of $467.2 million, up 41% year over year. The upside was driven by sales of its four approved marketed therapies for Duchenne muscular dystrophy (DMD). The reported figure beat the Zacks Consensus Estimate of $399.9 million. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar Sarepta's commercial portfolio includes three approved RNA-based PMO therapies — Exondys 51, Vyondys 53 and Amondys 45 — and the one-shot gene therapy Elevidys, all targeting DMD indication. SRPT product revenues rose 39% year over year to about $430 million, driven by increased demand for its marketed products. The metric beat the Zacks Consensus Estimate
Show less
Read more
Impact Snapshot
Event Time:
TMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TMO alerts
High impacting Thermo Fisher Scientific Inc news events
Weekly update
A roundup of the hottest topics
TMO
News
- Navigating the Inflation Reduction Act: Reassessing Evidence and Value Needs for Price Negotiations, Upcoming Webinar Hosted by XtalksPR Web
- Nanotechnology Market Is Expected To Reach a Revenue Of USD 74.9 Billion By 2033, At 34.3% CAGR: Dimension Market Research [Yahoo! Finance]Yahoo! Finance
- mRNA Synthesis & Manufacturing Market - Global Forecast to 2029 [Yahoo! Finance]Yahoo! Finance
- Thermo Fisher Scientific to Present at the Wolfe 2024 Healthcare Conference on November 19, 2024Business Wire
- Thermo Fisher Scientific Inc. (TMO): Among the Best Low Volatility Stocks to Invest In Now [Yahoo! Finance]Yahoo! Finance
TMO
Earnings
- 10/23/24 - Beat
TMO
Sec Filings
- 11/12/24 - Form 4
- 11/8/24 - Form 144
- 11/8/24 - Form 4
- TMO's page on the SEC website